From the Basics to Next Line Therapy: ALK + NSCLC
ALK fusions represent 3-5% of newly diagnosed non-small cell lung cancers but several therapeutic options do exist. Lung Cancer Considered host Dr. Narjust Florez and guests Dr. Christine Lovly from ...
27 Helmi 202446min
Best Practice for RET NSCLC
Lung Cancer Considered Host Dr. Stephen Liu moderates a discussion in this podcast on RET as a therapeutic target. RET fusions are a known actionable alteration and this field has blossomed very quick...
20 Helmi 202434min
Biomarkers in Lung Cancer: Barriers to Implementation
Today, IASLC released its 2024 Biomarker Survey, following up on its survey conducted in 2019 which found that one-third of oncologists were unaware of evidence-based guidelines for these tests. To di...
16 Helmi 202445min
LCC in Cantonese Chinese: Barriers to Biomarker Testing
Today, IASLC released its 2024 Biomarker Survey, following up on its survey conducted in 2019 that found one-third of oncologists were unaware of evidence-based guidelines for these tests. To reach a ...
16 Helmi 202439min
LCC in Mandarin Chinese: Barriers to Biomarker Testing
Today, IASLC released its 2024 Biomarker Survey, following up on its survey conducted in 2019 which found one-third of oncologists were unaware of evidence-based guidelines for these tests. To reach a...
16 Helmi 202428min
LCC in French: Barriers to Biomarker Testing
Today, IASLC released its 2024 Biomarker Survey, following up on its survey conducted in 2019 that found one-third of oncologists were unaware of evidence-based guidelines for biomarker tests. To reac...
16 Helmi 202439min
LCC in French Canadian: Barriers to Biomarker Testing
Today, IASLC released its 2024 Biomarker Survey, following up on its survey conducted in 2019 that found one-third of oncologists were unaware of evidence-based guidelines for these tests. To reach a ...
16 Helmi 202445min
LCC in Portuguese: Barriers to Biomarker Testing
Today, IASLC released its 2024 Biomarker Survey, following up on its survey conducted in 2019 that found one-third of oncologists were unaware of evidence-based guidelines for these tests. To reach a ...
16 Helmi 202436min
